Home › Research › Tau biomarkers
Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO
Ismail Z, Leon R, Creese B, Ballard C, Robert P, Smith EE.. Molecular neurodegeneration, 2023-07-29
Topic: Amyloid, tau and blood-test diagnosis
Background Disease-modifying drug use necessitates better Alzheimer disease (AD) detection. Mild cognitive impairment (MCI) leverages cognitive decline to identify the risk group; similarly, mild behavioral impairment (MBI) leverages behavioral change. Adding MBI to MCI improves dementia prognostication over conventional approaches of incorporating neuropsychiatric symptoms (NPS).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ismail, Z., Leon, R., Creese, B., Ballard, C., Robert, P., & Smith, E. E. (2023). Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO. Molecular neurodegeneration. https://doi.org/10.1186/s13024-023-00631-6
Vancouver
Ismail Z, Leon R, Creese B, Ballard C, Robert P, Smith EE. Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO. Molecular neurodegeneration. 2023. doi:10.1186/s13024-023-00631-6. PMID: 37516848.
BibTeX
@article{ismail2023-37516848,
author = {Ismail, Z. and Leon, R. and Creese, B. and Ballard, C. and Robert, P. and Smith, E. E.},
title = {{Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO}},
journal = {Molecular neurodegeneration},
year = {2023},
doi = {10.1186/s13024-023-00631-6},
pmid = {37516848},
url = {https://doi.org/10.1186/s13024-023-00631-6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Mild cognitive impairment (MCI) leverages cognitive decline to identify the risk group; similarly, mild behavioral impairment (MBI) leverages behavioral change.
- Adding MBI to MCI improves dementia prognostication over conventional approaches of incorporating neuropsychiatric symptoms (NPS).
- Here, to determine if adding MBI would better identify AD, we interrogated associations between MBI in MCI, and cerebrospinal fluid biomarkers [β-amyloid (Aβ), phosphorylated-tau (p-tau), and total-tau (tau)-ATN], cross-sectionally and longitudinally.
- Methods Data were from two independent referral-based cohorts, ADNI (mean[SD] follow-up 3.14[1.07] years) and MEMENTO (4.25[1.40] years), collected 2003-2021.
Why it matters
This 4-year biomarker study in ADNI and MEMENTO examined whether adding mild behavioral impairment to mild cognitive impairment better identifies Alzheimer's disease using CSF biomarkers. It is an observational detection study and does not test any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Effect size43.5%; 46.2%; 5.52%
- Evidence strengthModerate
How this study scored 58/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurodegeneration) |
| Journal's citation record | 2 / 4 | Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 81 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 16.2 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 4 / 6 | Cited 14.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 3 / 4 | Cited 75 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Eric Edward Smith: h-index 127 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Calgary: institution h-index 1,028 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37516848) |
| Free to read | 2 / 2 | Free to read |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13024-023-00631-6
- PubMed: 37516848
- Original source →
- Free full text: Molecular Neurodegeneration →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers
Also tagged “examination”
840 studies in the library carry the topic tag “examination”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.